Other
Drug Facts
The following Structured Product Label (SPL) was submitted to the FDA by Blistex Inc. for the product Kanka Triple Action (NDC 10157-2127). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding other, otc - purpose, uses, methemoglobinemia warning, allergy alert, do not use, when using this product, otc - keep out of reach of children, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Drug Facts
| Active ingredients | Purpose |
|---|---|
| Benzocaine 20.0% (w/w) | Oral anesthetic/analgesic (oral pain reliever) |
| Menthol 2.0% (w/w) | Oral anesthetic/analgesic (oral pain reliever) |
Use of this product may cause methemoglobinemia, a serious condition that must be treated promptly because it reduces the amount of oxygen carried in blood. This can occur even if you have used this product before. Stop use and seek immediate medical attention if you or a child in your care develops:
do not use this product if you have a history of allergy to local anesthetics such as procaine, butacaine, benzocaine, or other "caine" anesthetics.
Keep out of reach of children.
If more than used for pain is accidentally swallowed, get medical help or contact a Poison Control Center right away.
| Adults and children 2 years of age and older | Apply to affected area up to 4 times daily or as directed by a dentist or doctor |
| Children between 2 and 12 years of age | Ask a doctor before use. Should be supervised in the use of this product |
| Children under 2 years of age | Do not use |
ascorbyl palmitate, cetylpyridinium chloride, PEG-75, phenoxyethanol, polyethylene glycol, sucralose, thymol
* Please review the disclaimer below.